Estimating the cost effectiveness of single agent and combination anti-viral treatment strategies for patients with chronic hepatitis B
Estimating the cost effectiveness of single agent and combination anti-viral treatment strategies for patients with chronic hepatitis B
Background: Anti-viral treatment can avoid or delay progressive liver disease resulting from ChronicHepatitis B. However, long term treatment is associated with high rates of resistance, resulting in theadoption of combination therapies despite limited evidence of benefit (in terms of efficacy or reducedresistance). Combination therapy is up to five times the cost of first-line monotherapy.Objective: To estimate the cost effectiveness of anti-viral treatments in combination, as sequencesand as monotherapies.Methods: A previously published economic model was adapted to include sequential and combinationtreatments as well as monotherapies. Evidence on effectiveness and resistance for established antiviralagents (lamivudine and adefovir) from a systematic review was supplemented by searches forevidence on effectiveness and resistance for sequential and combination treatment strategies.Results: Sequential and combination treatment strategies yield benefits over monotherapies, but atsubstantial additional costs (lamivudine followed by adefovir yields 0.5 additional QALYs at anadditional cost of £9,300 compared with lamivudine alone, whereas lamivudine in combination withadefovir yields 0.9 additional QALYs at an additional cost of £23,000). At a cost effectivenessthreshold of £30,000, the population expected value of perfect information (EVPI) is £58 million.Parameters with greatest EVPI in the model relate to natural history of disease, treatment efficacy andresistance.
Jones, J.
270b303b-6bad-4be7-8ea0-63d0e8015c91
Shepherd, J.
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
6 July 2008
Jones, J.
270b303b-6bad-4be7-8ea0-63d0e8015c91
Shepherd, J.
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
Jones, J. and Shepherd, J.
(2008)
Estimating the cost effectiveness of single agent and combination anti-viral treatment strategies for patients with chronic hepatitis B.
5th Annual Meeting of Health Technology Assessment International, Montreal, Canada.
06 - 09 Jul 2008.
Record type:
Conference or Workshop Item
(Other)
Abstract
Background: Anti-viral treatment can avoid or delay progressive liver disease resulting from ChronicHepatitis B. However, long term treatment is associated with high rates of resistance, resulting in theadoption of combination therapies despite limited evidence of benefit (in terms of efficacy or reducedresistance). Combination therapy is up to five times the cost of first-line monotherapy.Objective: To estimate the cost effectiveness of anti-viral treatments in combination, as sequencesand as monotherapies.Methods: A previously published economic model was adapted to include sequential and combinationtreatments as well as monotherapies. Evidence on effectiveness and resistance for established antiviralagents (lamivudine and adefovir) from a systematic review was supplemented by searches forevidence on effectiveness and resistance for sequential and combination treatment strategies.Results: Sequential and combination treatment strategies yield benefits over monotherapies, but atsubstantial additional costs (lamivudine followed by adefovir yields 0.5 additional QALYs at anadditional cost of £9,300 compared with lamivudine alone, whereas lamivudine in combination withadefovir yields 0.9 additional QALYs at an additional cost of £23,000). At a cost effectivenessthreshold of £30,000, the population expected value of perfect information (EVPI) is £58 million.Parameters with greatest EVPI in the model relate to natural history of disease, treatment efficacy andresistance.
This record has no associated files available for download.
More information
Published date: 6 July 2008
Venue - Dates:
5th Annual Meeting of Health Technology Assessment International, Montreal, Canada, 2008-07-06 - 2008-07-09
Organisations:
Faculty of Medicine
Identifiers
Local EPrints ID: 345435
URI: http://eprints.soton.ac.uk/id/eprint/345435
PURE UUID: 9f523286-4c6f-41ac-8584-9493852d25b1
Catalogue record
Date deposited: 20 Nov 2012 14:47
Last modified: 23 Jul 2022 01:38
Export record
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
